Literature DB >> 24129063

NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Christelle Charbel1, Romain H Fontaine1, Gabriel G Malouf2, Arnaud Picard3, Natacha Kadlub3, Nizar El-Murr1, Alexandre How-Kit4, Xiaoping Su5, Aurore Coulomb-L'Hermine6, Jorg Tost7, Samia Mourah8, Selim Aractingi9, Sarah Guégan10.   

Abstract

Congenital melanocytic nevus (CMN) is a particular melanocytic in utero proliferation characterized by an increased risk of melanoma transformation during infancy or adulthood. NRAS and BRAF mutations have consistently been reported in CMN samples, but until recently results have been contradictory. We therefore studied a series of large and giant CMNs and compared them with small and medium CMNs using Sanger sequencing, pyrosequencing, high-resolution melting analysis, and mutation enrichment by an enhanced version of ice-COLD-PCR. Large-giant CMNs displayed NRAS mutations in 94.7% of cases (18/19). At that point, the role of additional mutations in CMN pathogenesis had to be investigated. We therefore performed exome sequencing on five specimens of large-giant nevi. The results showed that NRAS mutation was the sole recurrent somatic event found in such melanocytic proliferations. The genetic profile of small-medium CMNs was significantly different, with 70% of cases bearing NRAS mutations and 30% showing BRAF mutations. These findings strongly suggest that NRAS mutations are sufficient to drive melanocytic benign proliferations in utero.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129063     DOI: 10.1038/jid.2013.429

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

Review 1.  Genetic alterations in melanocytic tumors.

Authors:  Minoru Takata; Toshiaki Saida
Journal:  J Dermatol Sci       Date:  2006-07       Impact factor: 4.563

Review 2.  Melanoma risk in congenital melanocytic naevi: a systematic review.

Authors:  S Krengel; A Hauschild; T Schäfer
Journal:  Br J Dermatol       Date:  2006-07       Impact factor: 9.302

3.  Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.

Authors:  Barbara Dessars; Linda E De Raeve; Renato Morandini; Anne Lefort; Hakim El Housni; Ghanem E Ghanem; Benoît J Van den Eynde; Wenbin Ma; Diane Roseeuw; Gilbert Vassart; Frédérick Libert; Pierre Heimann
Journal:  J Invest Dermatol       Date:  2008-07-17       Impact factor: 8.551

4.  Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification.

Authors:  Alexandre How Kit; Nicolas Mazaleyrat; Antoine Daunay; Helene Myrtue Nielsen; Benoît Terris; Jörg Tost
Journal:  Hum Mutat       Date:  2013-09-17       Impact factor: 4.878

5.  Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study.

Authors:  A A Marghoob; S P Schoenbach; A W Kopf; S J Orlow; R Nossa; R S Bart
Journal:  Arch Dermatol       Date:  1996-02

6.  Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population.

Authors:  Di Wu; Mei Wang; Xingang Wang; Ningbei Yin; Tao Song; Haidong Li; Jun Yu; Duen-Mei Wang; Zhenmin Zhao
Journal:  Am J Dermatopathol       Date:  2011-06       Impact factor: 1.533

Review 7.  Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis.

Authors:  M DeDavid; S J Orlow; N Provost; A A Marghoob; B K Rao; Q Wasti; C L Huang; A W Kopf; R S Bart
Journal:  J Am Acad Dermatol       Date:  1996-10       Impact factor: 11.527

8.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

9.  Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

Authors:  Veronica A Kinsler; Anna C Thomas; Miho Ishida; Neil W Bulstrode; Sam Loughlin; Sandra Hing; Jane Chalker; Kathryn McKenzie; Sayeda Abu-Amero; Olga Slater; Estelle Chanudet; Rodger Palmer; Deborah Morrogh; Philip Stanier; Eugene Healy; Neil J Sebire; Gudrun E Moore
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551

10.  Germline melanocortin-1-receptor genotype is associated with severity of cutaneous phenotype in congenital melanocytic nevi: a role for MC1R in human fetal development.

Authors:  Veronica A Kinsler; Sayeda Abu-Amero; Peter Budd; Ian J Jackson; Susan M Ring; Kate Northstone; David J Atherton; Neil W Bulstrode; Philip Stanier; Raoul C Hennekam; Neil J Sebire; Gudrun E Moore; Eugene Healy
Journal:  J Invest Dermatol       Date:  2012-05-10       Impact factor: 8.551

View more
  43 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Multilineage ACTB mutation in a patient with fibro-osseous maxillary lesion and pilocytic astrocytoma.

Authors:  Young H Lim; Andrea B Burke; Mary S Roberts; Michael T Collins; Keith A Choate
Journal:  Am J Med Genet A       Date:  2018-08-27       Impact factor: 2.802

Review 3.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

4.  Clonogenic cell subpopulations maintain congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Natacha Kadlub; Aurore Coulomb-L'Hermine; Thomas Rouillé; Alexandre How-Kit; Philippe Moguelet; Jorg Tost; Arnaud Picard; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2014-10-13       Impact factor: 8.551

5.  Neurocutaneous melanocytosis (melanosis).

Authors:  Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-10-13       Impact factor: 1.475

6.  Therapeutic effects of targeting RAS-ERK signaling in giant congenital melanocytic nevi.

Authors:  Qingxiong Yu; Min Wu; Lingling Sheng; Qingfeng Li; Feng Xie
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

Review 7.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

8.  A large-scale collection of giant congenital melanocytic nevi: Clinical and histopathological characteristics.

Authors:  Min Wu; Qingxiong Yu; Bowen Gao; Lingling Sheng; Qingfeng Li; Feng Xie
Journal:  Exp Ther Med       Date:  2019-11-14       Impact factor: 2.447

9.  Prepubertal Melanoma Arising within a Medium-Sized Congenital Melanocytic Nevus.

Authors:  Leah Lalor; Klaus Busam; Kara Shah
Journal:  Pediatr Dermatol       Date:  2016-08-30       Impact factor: 1.588

Review 10.  Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.

Authors:  Young H Lim; Diana Ovejero; Kristina M Derrick; Michael T Collins; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2016-08       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.